Augmented glycaemic gap is a marker for an increased risk of post-infarct left ventricular systolic dysfunction

Table 2 Multivariate linear regression for the correlation between change in LVEF and other variables in non-DM

Non-DM patients	Univariate linear regression			Multivariate linear regression (Mode A, R² = 0.379)			Multivariate linear regression (Mode B, R² = 0.373)
Variables	Beta	95% CI	p-value	Beta	95% CI	p-value	Beta	95% CI	p-value
Age	− 0.029	− 0.134 to 0.076	0.582	0.077	− 0.015 to 0.169	0.099	0.098	0.004 to 0.193	0.042
Sex	− 3.811	− 7.428 to − 0.193	0.039	− 4.107	− 7.250 to − 0.964	0.011	− 4.337	− 7.490 to − 1.183	0.007
BMI	0.463	− 0.003 to 0.928	0.051	0.286	− 0.109 to 0.680	0.155	0.318	− 0.078 to 0.714	0.115
Peak hs-CRP	− 0.152	− 0.304 to 0.001	0.051	− 0.185	− 0.312 to − 0.058	0.005	− 0.190	− 0.318 to − 0.063	0.004
Baseline LVEF	− 0.469	− 0.596 to − 0.342	< 0.001	− 0.492	− 0.614 to − 0.370	< 0.001	− 0.498	− 0.621 to − 0.375	< 0.001
Total ischemic time	− 0.004	− 0.012 to 0.004	0.318	− 0.005	− 0.011 to 0.001	0.114	− 0.005	− 0.011 to 0.002	0.148
No. of diseased vessels	− 0.516	− 1.958 to 0.927	0.481	− 0.171	− 1.364 to 1.022	0.778	− 0.174	− 1.374 to 1.026	0.775
ABG	− 0.866	− 1.634 to − 0.099	0.027				− 1.124	− 1.795 to − 0.453	0.001
Glycemic gap	− 1.116	− 1.901 to − 0.331	0.006	− 1.214	− 1.886 to − 0.541	< 0.001

Change in LVEF was defined as LVEF at 6-month follow-up minus baseline LVEF
DM diabetes mellitus, BMI body mass index, hs-CRP hypersensitive C-reactive protein, LVEF left ventricular ejection fraction, Total ischemic time the period from symptom onset to reopening of infarction-associated artery, ABG admission blood glucose

ISSN: 1475-2840